These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 22205192)

  • 1. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
    Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
    Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
    Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
    Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
    Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
    Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.
    Madadi P; Amstutz U; Rieder M; Ito S; Fung V; Hwang S; Turgeon J; Michaud V; Koren G; Carleton BC;
    J Popul Ther Clin Pharmacol; 2013; 20(3):e369-96. PubMed ID: 24214521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics: why standard codeine doses can have serious toxicities or no therapeutic effect.
    Kelly PA
    Oncol Nurs Forum; 2013 Jul; 40(4):322-4. PubMed ID: 23803265
    [No Abstract]   [Full Text] [Related]  

  • 6. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
    VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
    Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 phenotype-specific codeine population pharmacokinetics.
    Linares OA; Fudin J; Schiesser WE; Daly Linares AL; Boston RC
    J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):4-15. PubMed ID: 25562725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice.
    Carranza-Leon D; Dickson AL; Gaedigk A; Stein CM; Chung CP
    Pharmacogenomics J; 2021 Aug; 21(4):484-490. PubMed ID: 33750887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.
    Badaoui S; Hopkins AM; Rodrigues AD; Miners JO; Sorich MJ; Rowland A
    AAPS J; 2021 Jan; 23(1):15. PubMed ID: 33404848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
    Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
    Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study.
    Willmann S; Edginton AN; Coboeken K; Ahr G; Lippert J
    Clin Pharmacol Ther; 2009 Dec; 86(6):634-43. PubMed ID: 19710640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
    Zahari Z; Ismail R
    Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.
    Gammal RS; Crews KR; Haidar CE; Hoffman JM; Baker DK; Barker PJ; Estepp JH; Pei D; Broeckel U; Wang W; Weiss MJ; Relling MV; Hankins J
    Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27335380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reviewing pharmacogenetics to advance precision medicine for opioids.
    Magarbeh L; Gorbovskaya I; Le Foll B; Jhirad R; Müller DJ
    Biomed Pharmacother; 2021 Oct; 142():112060. PubMed ID: 34523422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O-demethylation of codeine to morphine inhibited by low-dose levomepromazine.
    Vevelstad M; Pettersen S; Tallaksen C; Brørs O
    Eur J Clin Pharmacol; 2009 Aug; 65(8):795-801. PubMed ID: 19308365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Use of Codeine and Tramadol in the Pediatric Population-What is the Verdict Now?
    Fortenberry M; Crowder J; So TY
    J Pediatr Health Care; 2019 Jan; 33(1):117-123. PubMed ID: 30545525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.
    Smith DM; Weitzel KW; Elsey AR; Langaee T; Gong Y; Wake DT; Duong BQ; Hagen M; Harle CA; Mercado E; Nagoshi Y; Newsom K; Wright A; Rosenberg EI; Starostik P; Clare-Salzler MJ; Schmidt SO; Fillingim RB; Johnson JA; Cavallari LH
    Genet Med; 2019 Aug; 21(8):1842-1850. PubMed ID: 30670877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of impairment due to confirmed codeine use prior to a motor vehicle accident: role of pharmacogenomics.
    Wu AH; Kearney T
    J Forensic Leg Med; 2013 Nov; 20(8):1024-7. PubMed ID: 24237812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.